Pfizer Submits Data to FDA For Covid-19 Vaccine Booster Shot Approval

Pfizer and BioNTech announced yesterday that they’ve submitted initial data to the FDA to support the use of a shot for the Covid-19 vaccine. The booster dose has a significantly higher antibody response against the initial strain of the Coronavirus and the Delta and Beta variants compared to what was seen among people who’ve gotten the original doses. In a statement, Pfizer said “given the high levels of immune responses observed, a booster dose given within 6 to 12 months after the primary vaccination schedule may help maintain a high level of protection against Covid-19.”

According to CEO and co-founder of BioNTech, Dr. Ugur Shani “a booster vaccine could help reduce infection and disease rates in people who have previously been vaccinated and better control the spread of virus variants during the coming season.” Pfizer executives say they believe a booster shot will be needed soon but U.S. health officials say they’ve seen no indication one is needed yet. Last week, the FDA and CDC authorized and recommended a third dose of the vaccine for some immunocompromised people.